Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
暂无分享,去创建一个
N. Curtin | B. Durkacz | D. Newell | A. Calvert | Lan Z. Wang | Z. Hostomský | K. Maegley | S. Kyle | C. Calabrese | H. Thomas | D. Skalitzky | A. H. Calvert | Donald J. Skalitzky | Cathy C. Zhang | M. Batey | T. Boritzki | Janke Li
[1] G. Poirier,et al. Molecular and biochemical features of poly (ADP-ribose) metabolism , 1993, Molecular and Cellular Biochemistry.
[2] P. Sestili,et al. Structural requirements for inhibitors of poly(ADP-ribose) Polymerase , 2005, Journal of Cancer Research and Clinical Oncology.
[3] Hiroshi Suzuki,et al. Function of poly(ADP-ribose) polymerase in response to DNA damage: Gene-disruption study in mice , 1999, Molecular and Cellular Biochemistry.
[4] N. Curtin,et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. , 2002, Journal of medicinal chemistry.
[5] T. Dawson,et al. Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor , 2002, Science.
[6] L. Tentori,et al. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. , 2002, Pharmacological research.
[7] N. Curtin,et al. Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361. , 2001 .
[8] S. Smith,et al. The world according to PARP. , 2001, Trends in biochemical sciences.
[9] N. Curtin,et al. Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly ( ADP-ribose ) Polymerase , 2022 .
[10] N. Curtin,et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] G. de Murcia,et al. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? , 2000, Mutation research.
[12] S. Shall,et al. From DNA damage and stress signalling to cell death : poly-ADP-ribosylation reactions , 2000 .
[13] A. Bürkle,et al. Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: Evidence for increased tumor cell apoptosis in vivo , 1999, Oncogene.
[14] S. Snyder,et al. Poly (ADP-ribose) polymerase, nitric oxide and cell death. , 1999, Trends in pharmacological sciences.
[15] T. Ochiya,et al. Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[16] V. Schreiber,et al. Involvement of poly(ADP-ribose) polymerase in base excision repair. , 1999, Biochimie.
[17] J. Ménissier-de murcia,et al. DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. , 1998, Nucleic acids research.
[18] M. Malanga,et al. Poly(ADP-ribose) Binds to Specific Domains of p53 and Alters Its DNA Binding Functions* , 1998, The Journal of Biological Chemistry.
[19] G. Schulz,et al. The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. , 1998, Journal of molecular biology.
[20] G. Schulz,et al. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. , 1998, Biochemistry.
[21] T. Kelly,et al. Identification of autonomously replicating sequence (ARS) elements in eukaryotic cells. , 1997, Methods.
[22] E. Wagner,et al. Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase , 1997, Oncogene.
[23] P. Chambon,et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[24] E. Jacobson,et al. Tissue NAD as a biochemical measure of niacin status in humans. , 1997, Methods in enzymology.
[25] T. Lindahl,et al. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. , 1995, Trends in biochemical sciences.
[26] N. Curtin,et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. , 1995, British Journal of Cancer.
[27] A. Bürkle,et al. trans-dominant inhibition of poly(ADP-ribosyl)ation sensitizes cells against gamma-irradiation and N-methyl-N'-nitro-N-nitrosoguanidine but does not limit DNA replication of a polyomavirus replicon , 1995, Molecular and cellular biology.
[28] D. Hunting,et al. A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[29] E. Wagner,et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. , 1995, Genes & development.
[30] G. Marsischky,et al. Role of Glutamic Acid 988 of Human Poly-ADP-ribose Polymerase in Polymer Formation , 1995, The Journal of Biological Chemistry.
[31] N. Curtin,et al. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. , 1995, Biochimie.
[32] G. W. Potter,et al. Analysis of Biological Molecules: An introduction to principles, instrumentation and techniques , 1994 .
[33] G. de Murcia,et al. Poly(ADP-ribose) polymerase: a molecular nick-sensor. , 1994, Trends in biochemical sciences.
[34] J. Hoeijmakers,et al. Overproduction of the poly(ADP‐ribose) polymerase DNA‐binding domain blocks alkylation‐induced DNA repair synthesis in mammalian cells. , 1993, The EMBO journal.
[35] Laurence H. Baker,et al. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development , 1992, Developments in Oncology.
[36] J. Sebolt-Leopold,et al. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. , 1991, Anti-cancer drug design.
[37] G. de Murcia,et al. Inhibition of poly(ADP-ribosyl)ation by overexpressing the poly(ADP-ribose) polymerase DNA-binding domain in mammalian cells. , 1990, The Journal of biological chemistry.
[38] D. Scudiero,et al. New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.
[39] F. Althaus,et al. Poly(ADP-ribose) catabolism in mammalian cells exposed to DNA-damaging agents. , 1989, Mutation research.
[40] N. Berger. Poly(ADP-ribose) in the cellular response to DNA damage. , 1985, Radiation research.
[41] Z. Matsuda,et al. Poly (ADP-Ribose) synthetase. Separation and identification of three proteolytic fragments as the substrate-binding domain, the DNA-binding domain, and the automodification domain. , 1984, The Journal of biological chemistry.
[42] J. Zhang,et al. Poly(ADP-ribose) synthetase. , 1984, Methods in enzymology.
[43] M. R. Purnell,et al. Novel inhibitors of poly(ADP-ribose) synthetase. , 1980, The Biochemical journal.
[44] B. Durkacz,et al. (ADP-ribose)n participates in DNA excision repair , 1980, Nature.
[45] T. Chen,et al. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. , 1977, Experimental cell research.
[46] T. Sugimura,et al. Splitting of the ribose-ribose linkage of poly(adenosine diphosphate-robose) by a calf thymus extract. , 1971, The Journal of biological chemistry.